Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03487666
Title OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Georgetown University
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.